High throughput crystallography of TB drug targets

A. C. Murillo, H. Y. Li, T. Alber, E. N. Baker, James M Berger, L. T. Cherney, M. M. Cherney, Yoon Song Cho, D. Eisenberg, C. R. Garen, C. W. Goulding, L. W. Hung, T. R. Ioerger, W. R. Jacobs, M. N G James, C. Kim, I. Krieger, J. S. Lott, R. Sankaranarayanan, B. W. SegelkeT. C. Terwilliger, F. Wang, S. Wang, J. C. Sacchettini

Research output: Contribution to journalArticle

Abstract

Tuberculosis (TB) infects one-third of the world population. Despite 50 years of available drug treatments, TB continues to increase at a significant rate. The failure to control TB stems in part from the expense of delivering treatment to infected individuals and from complex treatment regimens. Incomplete treatment has fueled the emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). Reducing non-compliance by reducing the duration of chemotherapy will have a great impact on TB control. The development of new drugs that either kill persisting organisms, inhibit bacilli from entering the persistent phase, or convert the persistent bacilli into actively growing cells susceptible to our current drugs will have a positive effect. We are taking a 'multidisciplinary approach that will identify and characterize new drug targets that are essential for persistent Mtb. Targets are exposed to a battery of analyses including microarray experiments, bioinformatics, and genetic techniques to prioritize potential drug targets from Mtb for structural analysis. Our core structural genomics pipeline works with the individual laboratories to produce diffraction quality crystals of targeted proteins, and structural analysis will be completed by the individual laboratories. We also have capabilities for functional analysis and the virtual ligand screening to identify novel inhibitors for target validation. Our overarching goals are to increase the knowledge of Mtb pathogenesis using the TB research community to drive structural genomics, particularly related to persistence, develop a central repository for TB research reagents, and discover chemical inhibitors of drug targets for future development of lead compound.

Original languageEnglish (US)
Pages (from-to)127-139
Number of pages13
JournalInfectious Disorders - Drug Targets
Volume7
Issue number2
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Crystallography
Tuberculosis
Mycobacterium tuberculosis
Pharmaceutical Preparations
Genomics
Bacillus
Essential Drugs
Genetic Techniques
Therapeutics
Microarray Analysis
Computational Biology
Research
Ligands
Drug Therapy
Population
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Microbiology (medical)
  • Pharmacology

Cite this

Murillo, A. C., Li, H. Y., Alber, T., Baker, E. N., Berger, J. M., Cherney, L. T., ... Sacchettini, J. C. (2007). High throughput crystallography of TB drug targets. Infectious Disorders - Drug Targets, 7(2), 127-139. https://doi.org/10.2174/187152607781001853

High throughput crystallography of TB drug targets. / Murillo, A. C.; Li, H. Y.; Alber, T.; Baker, E. N.; Berger, James M; Cherney, L. T.; Cherney, M. M.; Cho, Yoon Song; Eisenberg, D.; Garen, C. R.; Goulding, C. W.; Hung, L. W.; Ioerger, T. R.; Jacobs, W. R.; James, M. N G; Kim, C.; Krieger, I.; Lott, J. S.; Sankaranarayanan, R.; Segelke, B. W.; Terwilliger, T. C.; Wang, F.; Wang, S.; Sacchettini, J. C.

In: Infectious Disorders - Drug Targets, Vol. 7, No. 2, 06.2007, p. 127-139.

Research output: Contribution to journalArticle

Murillo, AC, Li, HY, Alber, T, Baker, EN, Berger, JM, Cherney, LT, Cherney, MM, Cho, YS, Eisenberg, D, Garen, CR, Goulding, CW, Hung, LW, Ioerger, TR, Jacobs, WR, James, MNG, Kim, C, Krieger, I, Lott, JS, Sankaranarayanan, R, Segelke, BW, Terwilliger, TC, Wang, F, Wang, S & Sacchettini, JC 2007, 'High throughput crystallography of TB drug targets', Infectious Disorders - Drug Targets, vol. 7, no. 2, pp. 127-139. https://doi.org/10.2174/187152607781001853
Murillo, A. C. ; Li, H. Y. ; Alber, T. ; Baker, E. N. ; Berger, James M ; Cherney, L. T. ; Cherney, M. M. ; Cho, Yoon Song ; Eisenberg, D. ; Garen, C. R. ; Goulding, C. W. ; Hung, L. W. ; Ioerger, T. R. ; Jacobs, W. R. ; James, M. N G ; Kim, C. ; Krieger, I. ; Lott, J. S. ; Sankaranarayanan, R. ; Segelke, B. W. ; Terwilliger, T. C. ; Wang, F. ; Wang, S. ; Sacchettini, J. C. / High throughput crystallography of TB drug targets. In: Infectious Disorders - Drug Targets. 2007 ; Vol. 7, No. 2. pp. 127-139.
@article{6233149af504473fa96c4c863787028d,
title = "High throughput crystallography of TB drug targets",
abstract = "Tuberculosis (TB) infects one-third of the world population. Despite 50 years of available drug treatments, TB continues to increase at a significant rate. The failure to control TB stems in part from the expense of delivering treatment to infected individuals and from complex treatment regimens. Incomplete treatment has fueled the emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). Reducing non-compliance by reducing the duration of chemotherapy will have a great impact on TB control. The development of new drugs that either kill persisting organisms, inhibit bacilli from entering the persistent phase, or convert the persistent bacilli into actively growing cells susceptible to our current drugs will have a positive effect. We are taking a 'multidisciplinary approach that will identify and characterize new drug targets that are essential for persistent Mtb. Targets are exposed to a battery of analyses including microarray experiments, bioinformatics, and genetic techniques to prioritize potential drug targets from Mtb for structural analysis. Our core structural genomics pipeline works with the individual laboratories to produce diffraction quality crystals of targeted proteins, and structural analysis will be completed by the individual laboratories. We also have capabilities for functional analysis and the virtual ligand screening to identify novel inhibitors for target validation. Our overarching goals are to increase the knowledge of Mtb pathogenesis using the TB research community to drive structural genomics, particularly related to persistence, develop a central repository for TB research reagents, and discover chemical inhibitors of drug targets for future development of lead compound.",
author = "Murillo, {A. C.} and Li, {H. Y.} and T. Alber and Baker, {E. N.} and Berger, {James M} and Cherney, {L. T.} and Cherney, {M. M.} and Cho, {Yoon Song} and D. Eisenberg and Garen, {C. R.} and Goulding, {C. W.} and Hung, {L. W.} and Ioerger, {T. R.} and Jacobs, {W. R.} and James, {M. N G} and C. Kim and I. Krieger and Lott, {J. S.} and R. Sankaranarayanan and Segelke, {B. W.} and Terwilliger, {T. C.} and F. Wang and S. Wang and Sacchettini, {J. C.}",
year = "2007",
month = "6",
doi = "10.2174/187152607781001853",
language = "English (US)",
volume = "7",
pages = "127--139",
journal = "Infectious Disorders - Drug Targets",
issn = "1871-5265",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - High throughput crystallography of TB drug targets

AU - Murillo, A. C.

AU - Li, H. Y.

AU - Alber, T.

AU - Baker, E. N.

AU - Berger, James M

AU - Cherney, L. T.

AU - Cherney, M. M.

AU - Cho, Yoon Song

AU - Eisenberg, D.

AU - Garen, C. R.

AU - Goulding, C. W.

AU - Hung, L. W.

AU - Ioerger, T. R.

AU - Jacobs, W. R.

AU - James, M. N G

AU - Kim, C.

AU - Krieger, I.

AU - Lott, J. S.

AU - Sankaranarayanan, R.

AU - Segelke, B. W.

AU - Terwilliger, T. C.

AU - Wang, F.

AU - Wang, S.

AU - Sacchettini, J. C.

PY - 2007/6

Y1 - 2007/6

N2 - Tuberculosis (TB) infects one-third of the world population. Despite 50 years of available drug treatments, TB continues to increase at a significant rate. The failure to control TB stems in part from the expense of delivering treatment to infected individuals and from complex treatment regimens. Incomplete treatment has fueled the emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). Reducing non-compliance by reducing the duration of chemotherapy will have a great impact on TB control. The development of new drugs that either kill persisting organisms, inhibit bacilli from entering the persistent phase, or convert the persistent bacilli into actively growing cells susceptible to our current drugs will have a positive effect. We are taking a 'multidisciplinary approach that will identify and characterize new drug targets that are essential for persistent Mtb. Targets are exposed to a battery of analyses including microarray experiments, bioinformatics, and genetic techniques to prioritize potential drug targets from Mtb for structural analysis. Our core structural genomics pipeline works with the individual laboratories to produce diffraction quality crystals of targeted proteins, and structural analysis will be completed by the individual laboratories. We also have capabilities for functional analysis and the virtual ligand screening to identify novel inhibitors for target validation. Our overarching goals are to increase the knowledge of Mtb pathogenesis using the TB research community to drive structural genomics, particularly related to persistence, develop a central repository for TB research reagents, and discover chemical inhibitors of drug targets for future development of lead compound.

AB - Tuberculosis (TB) infects one-third of the world population. Despite 50 years of available drug treatments, TB continues to increase at a significant rate. The failure to control TB stems in part from the expense of delivering treatment to infected individuals and from complex treatment regimens. Incomplete treatment has fueled the emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). Reducing non-compliance by reducing the duration of chemotherapy will have a great impact on TB control. The development of new drugs that either kill persisting organisms, inhibit bacilli from entering the persistent phase, or convert the persistent bacilli into actively growing cells susceptible to our current drugs will have a positive effect. We are taking a 'multidisciplinary approach that will identify and characterize new drug targets that are essential for persistent Mtb. Targets are exposed to a battery of analyses including microarray experiments, bioinformatics, and genetic techniques to prioritize potential drug targets from Mtb for structural analysis. Our core structural genomics pipeline works with the individual laboratories to produce diffraction quality crystals of targeted proteins, and structural analysis will be completed by the individual laboratories. We also have capabilities for functional analysis and the virtual ligand screening to identify novel inhibitors for target validation. Our overarching goals are to increase the knowledge of Mtb pathogenesis using the TB research community to drive structural genomics, particularly related to persistence, develop a central repository for TB research reagents, and discover chemical inhibitors of drug targets for future development of lead compound.

UR - http://www.scopus.com/inward/record.url?scp=34547095491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547095491&partnerID=8YFLogxK

U2 - 10.2174/187152607781001853

DO - 10.2174/187152607781001853

M3 - Article

C2 - 17970224

AN - SCOPUS:34547095491

VL - 7

SP - 127

EP - 139

JO - Infectious Disorders - Drug Targets

JF - Infectious Disorders - Drug Targets

SN - 1871-5265

IS - 2

ER -